Payment overview · 2025
General Payments
$710.99
39 reported records · 12 companies
Healthcare provider profile · identity verified
Tara Williams-Matney, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GRUNDY, VA · NPI 1417192543
Verified facts
What the public records show
CMS Open Payments records show Tara Williams-Matney, ARNP received $710.99 in general payments during 2025 across 39 reported records.
Axsome Therapeutics, Inc. accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $176.48 | 24.8% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $160.48 | 22.6% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $106.15 | 14.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.32 | 10.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.68 | 7.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.75 | 5.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.88 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.56 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.45 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.41 | 2.2% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $15.17 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.66 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $710.99 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $176.48 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $160.48 | 10 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $106.15 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.32 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.32 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 308 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 198 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
198 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
308 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
198 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2045 | 282 |
| Gabapentin | Gabapentin | 1527 | 223 |
| Lisinopril | Lisinopril | 1268 | 215 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1197 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1020 | 145 |
| Metformin Hcl | Metformin Hcl | 1010 | 174 |
| Pantoprazole Sodium | Pantoprazole Sodium | 973 | 179 |
| Tamsulosin Hcl | Tamsulosin Hcl | 875 | 148 |
| Losartan Potassium | Losartan Potassium | 819 | 157 |
| Omeprazole | Omeprazole | 786 | 145 |
| Atenolol | Atenolol | 713 | 123 |
| Montelukast Sodium | Montelukast Sodium | 695 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 666 | 140 |
| Alprazolam | Alprazolam | 641 | 93 |
| Tramadol Hcl | Tramadol Hcl | 517 | 89 |
| Ibuprofen | Ibuprofen | 469 | 138 |
| Tizanidine Hcl | Tizanidine Hcl | 446 | 86 |
| Trazodone Hcl | Trazodone Hcl | 422 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 417 | 79 |
| Furosemide | Furosemide | 416 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 407 | 78 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 371 | 60 |
| Baclofen | Baclofen | 361 | 96 |
| Escitalopram Oxalate | Escitalopram Oxalate | 361 | 67 |
| Meloxicam | Meloxicam | 360 | 73 |
| Pregabalin | Pregabalin | 337 | 68 |
| Potassium Chloride | Potassium Chloride | 319 | 61 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 314 | 69 |
| Methylprednisolone | Methylprednisolone | 314 | 224 |
| Pravastatin Sodium | Pravastatin Sodium | 314 | 53 |
| Mounjaro | Tirzepatide | 308 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 307 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 300 | 203 |
| Eliquis | Apixaban | 294 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 294 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 59 |
| Sertraline Hcl | Sertraline Hcl | 284 | 43 |
| Ondansetron Odt | Ondansetron | 282 | 106 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 279 | 86 |
| Citalopram Hbr | Citalopram Hydrobromide | 273 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 253 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 250 | 36 |
| Azithromycin | Azithromycin | 240 | 180 |
| Celecoxib | Celecoxib | 230 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 207 | 51 |
| Glipizide | Glipizide | 204 | 33 |
| Linzess | Linaclotide | 198 | 51 |
| Ozempic | Semaglutide | 198 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 197 | 37 |
| Carvedilol | Carvedilol | 195 | 33 |
| Fluconazole | Fluconazole | 191 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 59 |
| Fenofibrate | Fenofibrate Nanocrystallized | 180 | 38 |
| Glimepiride | Glimepiride | 180 | 33 |
| Lorazepam | Lorazepam | 174 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 168 | 23 |
| Finasteride | Finasteride | 167 | 24 |
| Famotidine | Famotidine | 149 | 35 |
| Allopurinol | Allopurinol | 143 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 40 |
| Clonazepam | Clonazepam | 142 | 22 |
| Jardiance | Empagliflozin | 142 | 22 |
| Sucralfate | Sucralfate | 140 | 37 |
| Mirtazapine | Mirtazapine | 138 | 19 |
| Glipizide Er | Glipizide | 136 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 134 | 92 |
| Ezetimibe | Ezetimibe | 133 | 23 |
| Simvastatin | Simvastatin | 129 | 23 |
| Clonidine Hcl | Clonidine Hcl | 127 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 126 | 20 |
| Meclizine Hcl | Meclizine Hcl | 126 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 16 |
| Naproxen | Naproxen | 121 | 27 |
| Nitroglycerin | Nitroglycerin | 118 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 115 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 114 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 111 | 30 |
| Bumetanide | Bumetanide | 107 | 25 |
| Buspirone Hcl | Buspirone Hcl | 106 | 21 |
| Amoxicillin | Amoxicillin | 100 | 73 |
| Lansoprazole | Lansoprazole | 97 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 15 |
| Levofloxacin | Levofloxacin | 89 | 77 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 68 |
| Paroxetine Hcl | Paroxetine Hcl | 88 | 15 |
| Doxepin Hcl | Doxepin Hcl | 82 | suppressed |
| Entresto | Sacubitril/Valsartan | 82 | 11 |
| Gemfibrozil | Gemfibrozil | 82 | 13 |
| Spironolactone | Spironolactone | 82 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 25 |
| Dexamethasone | Dexamethasone | 80 | 67 |
| Diltiazem Hcl | Diltiazem Hcl | 79 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 78 | 53 |
| Irbesartan | Irbesartan | 74 | 13 |
| Memantine Hcl | Memantine Hcl | 74 | 13 |
| Prednisone | Prednisone | 73 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 68 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 15 |
| Diazepam | Diazepam | 68 | 11 |
| Synthroid | Levothyroxine Sodium | 68 | 11 |
| Verapamil Er | Verapamil Hcl | 67 | suppressed |
| Methocarbamol | Methocarbamol | 65 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 64 | 11 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 63 | 12 |
| Valsartan | Valsartan | 63 | 14 |
| Cilostazol | Cilostazol | 62 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 62 | 13 |
| Alendronate Sodium | Alendronate Sodium | 60 | 13 |
| Etodolac | Etodolac | 60 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 57 | 11 |
| Ibu | Ibuprofen | 56 | 23 |
| Dutasteride | Dutasteride | 54 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | suppressed |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 49 | 42 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Nystatin | Nystatin | 47 | 20 |
| Penicillin V Potassium | Penicillin V Potassium | 47 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 21 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 39 |
| Promethazine Hcl | Promethazine Hcl | 45 | 11 |
| Lidocaine | Lidocaine | 43 | 11 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Zafirlukast | Zafirlukast | 38 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 37 | 33 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Progesterone | Progesterone, Micronized | 37 | suppressed |
| Ramipril | Ramipril | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 21 |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 36 | 24 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 12 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Acyclovir | Acyclovir | 34 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 19 |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 32 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 23 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Perphenazine | Perphenazine | 26 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Colchicine | Colchicine | 25 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Glipizide Xl | Glipizide | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 24 | 23 |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | 15 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | 11 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Dipyridamole | Dipyridamole | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Easy Comfort Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Eplerenone | Eplerenone | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nifedipine | Nifedipine | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $710.99 · 39 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, CAPLYTA, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VERQUVO, VRAYLAR, Vonjo | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error